103 related articles for article (PubMed ID: 356985)
1. Comparative disposition of phosphoramide mustard and other cyclophosphamide metabolites in the mouse using the Salmonella/mutagenesis assay.
Suling WJ; Struck RF; Woolley CW; Shannon WM
Cancer Treat Rep; 1978 Sep; 62(9):1321-8. PubMed ID: 356985
[No Abstract] [Full Text] [Related]
2. Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vivo in mice.
Hemminki K
Cancer Res; 1985 Sep; 45(9):4237-43. PubMed ID: 4028012
[TBL] [Abstract][Full Text] [Related]
3. Half-life of oxazaphosphorines in biological fluids.
Sladek NE; Powers JF; Grage GM
Drug Metab Dispos; 1984; 12(5):553-9. PubMed ID: 6149904
[TBL] [Abstract][Full Text] [Related]
4. Effects of phosphoramide mustard and acrolein, cytotoxic metabolites of cyclophosphamide, on mouse limb development in vitro.
Hales BF
Teratology; 1989 Jul; 40(1):11-20. PubMed ID: 2763206
[TBL] [Abstract][Full Text] [Related]
5. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation.
Sladek NE; Doeden D; Powers JF; Krivit W
Cancer Treat Rep; 1984 Oct; 68(10):1247-54. PubMed ID: 6395951
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetics of cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy.
Juma FD; Rogers HJ; Trounce JR
Br J Clin Pharmacol; 1980 Oct; 10(4):327-35. PubMed ID: 7448105
[No Abstract] [Full Text] [Related]
7. Glutathione conjugation with phosphoramide mustard and cyclophosphamide. A mechanistic study using tandem mass spectrometry.
Yuan ZM; Smith PB; Brundrett RB; Colvin M; Fenselau C
Drug Metab Dispos; 1991; 19(3):625-9. PubMed ID: 1680629
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the mutagenicity and teratogenicity of cyclophosphamide and its active metabolites, 4-hydroxycyclophosphamide, phosphoramide mustard, and acrolein.
Hales BF
Cancer Res; 1982 Aug; 42(8):3016-21. PubMed ID: 7046914
[No Abstract] [Full Text] [Related]
9. Pharmacokinetics of 4-hydroxycyclophosphamide and metabolites in the rat.
Hong PS; Srigritsanapol A; Chan KK
Drug Metab Dispos; 1991; 19(1):1-7. PubMed ID: 1673381
[TBL] [Abstract][Full Text] [Related]
10. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione.
Dirven HA; van Ommen B; van Bladeren PJ
Cancer Res; 1994 Dec; 54(23):6215-20. PubMed ID: 7954469
[TBL] [Abstract][Full Text] [Related]
11. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis.
Low JE; Borch RF; Sladek NE
Cancer Res; 1982 Mar; 42(3):830-7. PubMed ID: 7059981
[TBL] [Abstract][Full Text] [Related]
12. Blood levels of alkylating metabolites of cyclophosphamide in the mouse after iv or oral administration.
Struck RF; Alberts DS
Cancer Treat Rep; 1984 May; 68(5):765-70. PubMed ID: 6722832
[TBL] [Abstract][Full Text] [Related]
13. Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard.
Chang TK; Waxman DJ
Cancer Res; 1993 Jun; 53(11):2490-7. PubMed ID: 8495410
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide metabolism in children.
Yule SM; Boddy AV; Cole M; Price L; Wyllie R; Tasso MJ; Pearson AD; Idle JR
Cancer Res; 1995 Feb; 55(4):803-9. PubMed ID: 7850793
[TBL] [Abstract][Full Text] [Related]
15. Vomiting induced by cyclophosphamide and phosphoramide mustard in cats.
Fetting JH; McCarthy LE; Borison HL; Colvin M
Cancer Treat Rep; 1982 Aug; 66(8):1625-9. PubMed ID: 7105052
[TBL] [Abstract][Full Text] [Related]
16. Formation of a phosphoramide mustard-nucleotide adduct that is not by alkylation at the N7 position of guanine.
Maccubbin AE; Caballes L; Chheda GB; Struck RF; Gurtoo HL
Biochem Biophys Res Commun; 1989 Sep; 163(2):843-50. PubMed ID: 2783126
[TBL] [Abstract][Full Text] [Related]
17. The role of reactive metabolites in drug-induced teratogenesis.
Hales BF; Slott VL
Prog Clin Biol Res; 1987; 253():181-91. PubMed ID: 3432286
[No Abstract] [Full Text] [Related]
18. Trapping of DNA-reactive metabolites of therapeutic or carcinogenic agents by carbon-14-labeled synthetic polynucleotides.
Mehta JR; Ludlum DB
Cancer Res; 1982 Aug; 42(8):2996-9. PubMed ID: 7093949
[TBL] [Abstract][Full Text] [Related]
19. A cyclophosphamide/DNA phosphoester adduct formed in vitro and in vivo.
Maccubbin AE; Caballes L; Riordan JM; Huang DH; Gurtoo HL
Cancer Res; 1991 Feb; 51(3):886-92. PubMed ID: 1988129
[TBL] [Abstract][Full Text] [Related]
20. Investigation on cyclophosphamide treatment during the preimplantation period. II. In vitro studies on the effects of cyclophosphamide and its metabolites 4-OH-cyclophosphamide, phosphoramide mustard, and acrolein on blastulation of four-cell and eight-cell mouse embryos and on their subsequent development during implantation.
Spielmann H; Jacob-Müller U
Teratology; 1981 Feb; 23(1):7-13. PubMed ID: 7245091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
